EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanomedicine for Cancer and Autoimmune Immunotherapy

Ashi Ramavat iD, Priya Antil, Soniya Kaushik iD, Baby Kataria, Ramendra Pati Pandey iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262411941 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ashi Ramavat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Nanomedicine, Autoimmune Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanomedicine has now become a transformative platform that enhances the precision and efficacy of immunotherapy approaches and allows customizations like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nanoscale, researchers have been able to manipulate immune responses operating across spatial and temporal scales to address key limitations of conventional immunotherapy associated with working with immune response such as immune evasion, systemic toxicity, and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens, and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation, and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyNanomedicineAutoimmune DiseasesHumansNanoparticlesAnimals

Stichwörter der Autor:innen

CAR-T cell enhancementcytokine regulationexosome-mimetic nanoplatformstumor microenvironment (TME)

Autor:innen und Institutionen

  • Department of Biotechnology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India.
  • Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology (DCRUST), Sonepat 131001, Haryana, India.
  • Department of Microbiology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India.

ORCID-Profile: Ashi Ramavat, Soniya Kaushik, Ramendra Pati Pandey

Zitieren

APA

Ramavat, A., Antil, P., Kaushik, S., Kataria, B., & Pandey, R. P. (2025). Nanomedicine for Cancer and Autoimmune Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411941

Vancouver

Ramavat A, Antil P, Kaushik S, Kataria B, Pandey RP. Nanomedicine for Cancer and Autoimmune Immunotherapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411941

BibTeX
@article{Ramavat2025,
  author = {Ramavat, Ashi and Antil, Priya and Kaushik, Soniya and Kataria, Baby and Pandey, Ramendra Pati},
  title = {Nanomedicine for Cancer and Autoimmune Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262411941}
}
Kostenlos starten →